Dr. Weeks’ Comment: Prevention is the goal. Anti-oxidation is the method. Coconut oil, Medium chair triglycerides and herbs which stimulate CD 14 macrophages are proving to be clinically beneficial.
“…Our results showed improvements in both clinical and physiological outcomes for a disease that otherwise has no standard ameliorative remedy…”
Ask your doctor about helping you prevent dementia starting now.
Change your diet and life style to a brain healthy option and call SafaLab 360-341-2303 and order “Fuel for Thought” and “New Eden”.
Apr. 3, 2013 — The monetary cost of dementia in the United States ranges from $157 billion to $215 billion annually, making the disease more costly to the nation than either heart disease or cancer, according to a new RAND Corporation study.
The greatest economic cost of dementia is associated with providing institutional and home-based long-term care rather than medical services, according to the findings published in the April 4 edition of the New England Journal of Medicine…..
“The economic burden of caring for people in the United States with dementia is large and growing larger,” said Michael Hurd, the study’s lead author and a senior economist at RAND, a nonprofit research organization. “Our findings underscore the urgency of recent federal efforts to develop a coordinated plan to address the growing impact of dementia on American society.”
Dementia is a chronic disease of aging characterized by progressive cognitive decline that interferes with independent functioning. The illness includes Alzheimer’s disease and other disorders.
The study estimates that 14.7 percent of Americans aged 71 or older suffered from dementia in 2010, a number somewhat lower than what has been found in other, smaller studies.
The total economic cost of dementia in 2010 was estimated to be $109 billion for care purchased, and $159 billion to $215 billion when the monetary value of informal care is included. The range of estimates reflects two different methods researchers used to place a value on unpaid care. The per-person cost of dementia was $56,290 or $41,689. Medicare paid about $11 billion of dementia-related costs….
The cost of dementia care purchases ($109 billion) was similar to the estimated of the direct health care costs for heart disease ($102 billion) and significantly higher than the direct health costs for cancer ($77 billion). However, the costs for cancer and health disease do not include the cost of informal care, which is likely to be larger for dementia.
“There are no signs that the costs of dementia will decrease given that the nation will have a larger number of 85-year-olds in the future than we do today,” Hurd said. “Unless there is some sort of medical breakthrough, these costs will continue to rise.”
Other authors of the study are Francisco Martorell, Adeline Delavande and Kathleen J. Mullen of RAND and Kenneth M. Langa of the University of Michigan.
M.D. Hurd, P. Martorell, A. Delavande, K.J. Mullen, and K.M. Langa. Monetary Costs of Dementia in the United States. New England Journal of Medicine, 2013; DOI: 10.1056/NEJMsa1204629
AND NOW FOR SOME “CENTISIBLE” SOLUTIONS…
J Alzheimers Dis. 2012 Sep 13. [Epub ahead of print]
The Effect of an Aloe Polymannose Multinutrient Complex on Cognitive and Immune Functioning in Alzheimer’s Disease.
Department of Psychiatry & Behavioral Sciences, Miami, FL, USA.
Alzheimer’s disease (AD) is a leading killer of Americans, imparts a significant toll on the quality of life of the patient and primary caregiver, and results in inordinate costs in an already overburdened medical system. Prior studies on cholinesterase inhibitors among AD patients have shown minimal amelioration of disease symptoms and/or restoration of lost cognitive functioning. The effect of improved nutrition, particularly with dietary supplements, on cognitive functioning may offer an alternative strategy compared to standard treatment. The present pilot study investigated the effect of an aloe polymannose multinutrient complex (APMC) formula on cognitive and immune functioning over 12 months among adults diagnosed with AD. Subjects participated in an open-label trial and consumed 4 teaspoons per day of the APMC. The ADAS-cog, MMSE, ADCS-ADL, and SIB were administered at baseline and 3, 6, 9, and 12 months follow-up. Cytokines and lymphocyte and monocyte subsets were assessed at baseline and 12 months. The mean ADAS-cog cognition score significantly improved at 9 and 12 months from baseline, and 46% of our sample showed clinically-significant improvement (≥4-point change) from baseline to 12 months. Participants showed significant decreases in tumor necrosis factor-α, vascular endothelial growth factor, and interleukins-2 and-4. CD90+, CD95+CD3+, CD95+CD34+, CD95+CD90+, CD14+CD34+, CD14+CD90+, and CD14+CD95+ decreased significantly, whereas CD14+ significantly increased. Participants tolerated the APMC supplement with few, temporary adverse reactions. Our results showed improvements in both clinical and physiological outcomes for a disease that otherwise has no standard ameliorative remedy.
PMID: 22976077 [PubMed – as supplied by publisher]